Objective:

To enhance clinicians’ understanding of the clinical characteristics and management of PIP-TAZ-induced immune hemolytic anemia and immune thrombocytopenia, emphasizing the significance of timely recognition.

Key Findings:

• The patient exhibited symptoms of jaundice, severe hemolytic anemia, and thrombocytopenia after PIP-TAZ administration.
• Blood tests showed significantly elevated PIP-TAZ levels and the presence of drug-dependent antibodies.
• Prompt recognition and management led to the patient's full recovery within a week.

Interpretation:

Effective treatment strategies included discontinuation of PIP-TAZ, blood transfusions, IVIG, corticosteroid therapy, and monitoring of vital signs, with each approach tailored to the patient's response.

Limitations:

• The case highlights the rarity of DIIHA and DITP, which may lead to underdiagnosis, particularly in elderly patients.
• The specific mechanisms and structural fragments of PIP-TAZ that elicit immune responses remain unclear.

Conclusion:

This case underscores the importance of recognizing and managing drug-induced immune reactions promptly to prevent severe complications.